The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2020)Molecular classification of breast cancer Adv Anat Pathol 27 27-35

[3] Siegel RL(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet. 378 771-84

[4] Laversanne M(2019)Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen Expert Rev Clin Pharmacol 12 523-536

[5] Soerjomataram I(2013)PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics 23 643-647

[6] Jemal A(2020)Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group Clin Transl Sci 13 116-124

[7] Tsang JYS(2017)Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen Front Pharmacol 8 582-1429

[8] Tse GM(2021)Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: current status of a controversy Cancers (Basel) 13 771-557

[9] Davies C(2022)Frequencies of CYP2D6 genetic polymorphisms in Arab populations Hum Genomics 16 6-31

[10] Godwin J(2008)Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423-879

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2020)Molecular classification of breast cancer Adv Anat Pathol 27 27-35

[3] Siegel RL(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet. 378 771-84

[4] Laversanne M(2019)Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen Expert Rev Clin Pharmacol 12 523-536

[5] Soerjomataram I(2013)PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics 23 643-647

[6] Jemal A(2020)Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group Clin Transl Sci 13 116-124

[7] Tsang JYS(2017)Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen Front Pharmacol 8 582-1429

[8] Tse GM(2021)Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: current status of a controversy Cancers (Basel) 13 771-557

[9] Davies C(2022)Frequencies of CYP2D6 genetic polymorphisms in Arab populations Hum Genomics 16 6-31

[10] Godwin J(2008)Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 1423-879